TARGET-PBC: A 5-year Longitudinal Observational Study of Patients

Recruiting

18 years - 80 years

All

Phase N/A

180 participants needed

1 Location

Brief description of study

You are being asked to be in this research study because you have PBC (primary biliary cholangitis) which is an uncommon chronic cholestatic liver disease characterized by progressive inflammation and destruction of the interlobular bile ducts, ultimately leading to the development of biliary cirrhosis.

Detailed description of study

The goals of this study are to collect information on patients with PBC to determine the natural course of the liver disease and to determine if certain lifestyle changes or changes in diet or other treatments that may be recommended by your doctors can affect “PBC.”. Currently, there are 2 specific drugs, Ocaliva™ and ursodeoxycholic acid (UDCA), approved by the FDA (the Food and Drug Administration to treat PBC.

This research study aims to observe any treatment for PBC in a large number of people in a “real life” setting. Researchers are interested in observing how these treatments, lifestyle changes, and counseling work in patients who are treated by their doctors in routine practice.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: PBC,liver disease,primary billary Cholangitis
Age: 18 years - 80 years
Gender: All

Updated on 19 Feb 2024. Study ID: 826565

Pre-Screener

Compruebe si es elegible Ingrese los datos de contacto Selecciona un centro de estudios Select best time to contact

Do you have primary biliary cholangitis (PBC, sometimes called primary biliary cirrhosis)?

None

Yes No

Preview complete

The prescreener preview is complete. You may now close the preview.